| scholarly article | Q13442814 |
| P50 | author | Kypros Nicolaides | Q1795145 |
| David Krantz | Q59157188 | ||
| P2093 | author name string | Terrence W Hallahan | |
| Jonathan B Carmichael | |||
| David Janik | |||
| Hsiao-Pin Liu | |||
| P2860 | cites work | The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada. | Q51125785 |
| A CRITICAL EVALUATION OF SONAR "CROWN-RUMP LENGTH" MEASUREMENTS | Q55883094 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS) | Q57839618 | ||
| Serum alpha-fetoprotein in the three trimesters of pregnancy: effects of maternal characteristics and medical history | Q57917832 | ||
| First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein | Q61847846 | ||
| Maternal serum Down syndrome screening: Free β-protein is a more effective marker than human chorionic gonadotropin | Q67673897 | ||
| Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome | Q70056433 | ||
| An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities | Q72729435 | ||
| Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan | Q79789059 | ||
| Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting | Q83395075 | ||
| First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay | Q84406215 | ||
| Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures | Q87294866 | ||
| Early Administration of Low-Dose Aspirin for the Prevention of Preterm and Term Preeclampsia: A Systematic Review and Meta-Analysis | Q22306400 | ||
| DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study | Q34029044 | ||
| Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing | Q34256640 | ||
| Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. | Q34375938 | ||
| The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis | Q34540601 | ||
| Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service | Q35142853 | ||
| Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis | Q35552815 | ||
| Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening | Q35560414 | ||
| Incorporation of dried blood alpha fetoprotein into traditional first trimester Down syndrome screening service. | Q36402612 | ||
| Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units | Q37067727 | ||
| Screening for fetal aneuploidies at 11 to 13 weeks | Q37826399 | ||
| Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks | Q37826400 | ||
| Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. | Q40617657 | ||
| Rates of chromosome abnormalities at different maternal ages. | Q43663396 | ||
| Nearly a third of abnormalities found after first-trimester screening are different than expected: 10-year experience from a single center | Q43862864 | ||
| Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis | Q43872436 | ||
| First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing | Q43905798 | ||
| Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities | Q44259917 | ||
| First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. | Q44729421 | ||
| First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing | Q45839764 | ||
| Birthweight with gestation and maternal characteristics in live births and stillbirths | Q46599456 | ||
| Cell-free DNA analysis for noninvasive examination of trisomy | Q46784231 | ||
| Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. | Q46906958 | ||
| Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening | Q50122749 | ||
| Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level | Q50148910 | ||
| First-trimester growth patterns of aneuploid fetuses. | Q50969466 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 802-807 | |
| P577 | publication date | 2017-07-18 | |
| P1433 | published in | Prenatal Diagnosis | Q15760059 |
| P1476 | title | Expanded conventional first trimester screening | |
| P478 | volume | 37 |
| Q64096371 | Chromosomal Microarray Analysis versus Karyotyping in Fetuses with Increased Nuchal Translucency |
| Q89584336 | Down's Syndrome Screening in the First Trimester with Additional Serum Markers: Indian Parameters |
| Q92384321 | The Contingent Prenatal Screening Test for Down's Syndrome and Neural Tube Defects in West of Iran |
Search more.